Novel doxorubicin-monoclonal anti-carcinoembryonic antigen antibody immunoconjugate activity in vitro
✍ Scribed by Achilles Lau; Gervais Bérubé; Christopher H.J. Ford; Maureen Gallant
- Publisher
- Elsevier Science
- Year
- 1995
- Tongue
- English
- Weight
- 607 KB
- Volume
- 3
- Category
- Article
- ISSN
- 0968-0896
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract In order to analyze the epitope structure of carcinoembryonic antigen (CEA) and the idiotype network system, seven anti‐idiotypic monoclonal antibodies (anti‐Id MoAbs) were generated from a BALB/c mouse immunized with anti‐CEA MoAb P1‐356, which recognized a synthetic peptide P1 of CEA,
A bispecific monoclonal antibody (BsMAb) recognising carcinoembryonic antigen (CEA) and doxorubicin (Dox) was used in colorimetric microcytotoxicity assays with 3 human colon cancer cell lines (COLO320DM, SKCO1 and LS174T) showing no, high or medium CEA expression, respectively. The IC50 values for
## Abstract Biparatopic CEA, carcinoembryonic antigen (MAb) was newly designed and tested as to whether it enhanced the accuracy of tumor detection by reducing non‐specific binding in experimental radioimmunoguided surgery. Biparatopic MAb was prepared by using cross‐linking of reduced Fab′ fragmen
## Abstract ## Objective To clarify whether mouse monoclonal antibodies (mAb) against human thrombomodulin (TM), which react with human TM present on the endothelial cell (EC) surface, have anti–endothelial cell antibody (AECA) activity and influence antiinflammatory properties of human TM express